Post-marketing evaluation of the safety of influenza virus vaccine live, intranasal (Flumist) in healthy children and healthy adults 5-49 years of age
Phase of Trial: Phase IV
Latest Information Update: 07 Jan 2013
At a glance
- Drugs Influenza virus vaccine live (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors MedImmune
- 07 Jan 2013 Primary endpoints added as reported by ClinicalTrials.gov.
- 15 Sep 2009 Planned number of patients changed from 60000 to 66438 as reported by ClinicalTrials.gov.
- 15 Sep 2009 Planned end date changed from 1 Sep 2010 to 1 Jun 2010 as reported by ClinicalTrials.gov.